SCHEMBL29518151

SCHEMBL29518151

CC(C)(C)OC(=O)N1CCC[C@@H](Nc2ccc(I)cn2)C1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 6/20 0.48
HDAC4 P56524 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
DDB1 Q16531 1/20 0.45
CRBN Q96SW2 1/20 0.45
PARP1 P09874 1/20 0.44
FPR3 P25089 1/20 0.44
FPR2 P25090 1/20 0.44
HPGDS O60760 1/20 0.43
PIK3CD O00329 1/20 0.43
BTK Q06187 2/20 0.43
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
JAK2 O60674 1/20 0.43
JAK1 P23458 1/20 0.43
GABRA5 P31644 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28679078 1.00 USP30 (0.48) USP30HDAC4HDAC6DDB1CRBN
SCHEMBL28679080 1.00 USP30 (0.48) USP30HDAC4HDAC6DDB1CRBN
SCHEMBL18937698 0.88 USP30 (0.49) USP30HDAC4HDAC6DDB1CRBN
SCHEMBL889050 0.87 FPR2 (0.53) USP30HDAC4HDAC6DDB1CRBN
SCHEMBL1030155 0.87 FPR2 (0.53) USP30HDAC4HDAC6DDB1CRBN
SCHEMBL529396 0.87 USP30 (0.49) USP30HDAC4HDAC6DDB1CRBN
SCHEMBL29518225 0.86 ALDH1A1 (0.56) USP30DDB1CRBNJAK1ALDH1A1
SCHEMBL22825511 0.86 ALDH1A1 (0.56) USP30DDB1CRBNJAK1ALDH1A1
SCHEMBL19749791 0.86 ALDH1A1 (0.54) USP30HDAC4HDAC6DDB1CRBN
SCHEMBL31227721 0.85 USP30 (0.49) USP30HDAC4HDAC6PARP1PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12325696-B2 Indazole derivative, preparation method therefor, and pharmaceutical application thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2025-06-10 US disclosed
US-20220267304-A1 INDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2022-08-25 US disclosed
EP-3988547-A1 INDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF Jiangsu Hengrui Medicine Co., Ltd. (CN) 2022-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12325696-B2 Indazole derivative, preparation method therefor, and pharmaceutical application thereof CYP19A1, HSD17B11, CYP51A1 USP30 3873/4885HDAC4 1862/4885HDAC6 2767/4885
US-20220267304-A1 INDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF CYP19A1, HSD17B11, CYP51A1 USP30 3873/4885HDAC4 1862/4885HDAC6 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.